Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

IntroductionAtherosclerosis, the hardening and narrowing of the arteries, occurs due to the buildup of plaque on the inner walls of the arteries which can result in reduced blood flow to the organs and tissues. Risk factors such as smoking, chronic kidney disease, and aging can contribute to plaque formation.

Risk Factors 40

Risk Factors Blood Pressure Chest Pain Plaque 40

GEMMS

MAY 22, 2024

Traditional tools like stethoscopes, blood pressure gauges, and electrocardiograms (ECG) are fundamental for standard diagnostic practices. Gene-Based Analysis Predictive analytics is vital in reducing morbidity and mortality, with healthcare startups focusing on early risk prediction and disease detection.

Heart Disease 52

Heart Disease Blood Pressure Technology Innovation 52

DAIC

DECEMBER 8, 2023

There is clearer focus on risk factor modification—for example, weight loss and obesity prevention, physical activity, smoking cessation, limiting alcohol, and controlling blood pressure and other comorbidities—to help prevent AFib or ameliorate any recurrences or worsening of the disease.

Atrial Fibrillation 52

Atrial Fibrillation AFIB Strokes Stroke 52

DAIC

APRIL 7, 2024

Akshay Desai, MD “Compared to placebo, a single injection of zilebesiran resulted in clinically meaningful reductions in blood pressure at three months when added to commonly used antihypertensive treatments,” said Akshay Desai, MD, MPH , a cardiologist at Brigham and Women’s Hospital in Boston and a study coauthor. “In

Blood Pressure 111

Blood Pressure Heart Attack Heart attacks Hypertension 111

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

DAIC

JANUARY 19, 2024

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure. mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. Suman Pasupuleti, M.D.

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

CardiacWire

OCTOBER 6, 2024

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its blood pressure effects. Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF.

Heart Failure 59

Heart Failure Blood Pressure Kidney Disease Diabetes 59

Physiologically Speaking

DECEMBER 15, 2023

Effects of resistance training on traditional CVD risk factors Blood pressure Resistance exercise training has been shown to improve resting blood pressure in cohorts of healthy adults and adults with varying levels of high blood pressure. a higher metabolism).

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

Physiologically Speaking

DECEMBER 15, 2023

Effects of resistance training on traditional CVD risk factors Blood pressure Resistance exercise training has been shown to improve resting blood pressure in cohorts of healthy adults and adults with varying levels of high blood pressure. a higher metabolism).

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

Cardiometabolic Health Congress

JULY 17, 2024

Clinical Trial Results: Reduction in NAFLD activity score Improved fibrosis Consistent results across 1,759 patients, regardless of age, gender, type 2 diabetes status, or fibrosis stage 2. The label includes a “black box” warning for CV risk due to blood clots.

Tricuspid 59

Tricuspid Open-Heart Surgery Kidney Disease Pediatrics 59

Cardiometabolic Health Congress

JULY 10, 2024

Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidney disease, hypertension, and nephropathy progression. A Pioneering Journey: The Life and Legacy of Dr. George L. Bakris Dr. George L. When I heard of his passing, I felt quite sad.

Hypertension 52

Hypertension Education Blood Pressure Kidney Disease 52

DAIC

MAY 16, 2024

Among those ages 65 and older, nearly 50% who underwent limb amputation died within one year after surgery, according to the 2024 Heart Disease and Stroke Statistics: A Report of U.S. and Global Data From the American Heart Association. All patients with PAD should be treated with high-intensity statin therapy.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

Cardiometabolic Health Congress

JULY 25, 2023

Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Circulation

NOVEMBER 11, 2024

Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. Circulation, Volume 150, Issue Suppl_1 , Page A4121215-A4121215, November 12, 2024.

Myocardial Infarction 40

Myocardial Infarction Blood Pressure Heart Failure Kidney Disease 40

Stroke Journal

JANUARY 30, 2025

Background and Purpose:Chronic kidney disease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. female, 22.1%

Atherosclerosis 40

Atherosclerosis Kidney Disease Blood Pressure Biomarkers 40

DAIC

JANUARY 23, 2024

11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 For most individuals, these gastrointestinal effects markedly attenuate with longer-term therapy.34 μ/L on 0.6

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Physiologically Speaking

MAY 3, 2024

KNG1 and 2 are speculated to play a role in exercise’s effect on improving blood pressure and insulin sensitivity. All of the major HSPs were upregulated after exercise. Enzymes known as kininogenases 1 and 2 (KNG1 and KNG2) also increased after exercise.

Exercise 95

Exercise Physiology Research Kidney Disease 95

Frontiers in Cardiovascular Medicine

JANUARY 5, 2025

Patients in VERISEC were older and had more comorbidities (diabetes, advanced chronic kidney disease) compared to VICTORIA, with 20% having an estimated glomerular filtration rate below 30ml/min. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) 7,054.0)] pg/ml.

Heart Failure 52

Heart Failure Kidney Disease Blood Pressure Diabetes 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103